According to CDE information, Haihe Pharmaceuticals PI3Kα inhibitor CYH33 tablets, Lijin Bio-CD137 activating antibody LVGN6051 monoclonal antibody injection, and Lingke Pharmaceutical’s LNK01001 capsules have been approved for clinical use.
According to CDE public information, Haihe drug PI3K alpha inhibitor CYH33 tablets, Reediter bioCD137 activated antibody LVGN6051 monoclonal antibody injection and Lingke Pharmaceuticals LNK01001 capsules were approved clinically.